Koppikar Utpal
Koppikar Utpal's purchase track record
Koppikar Utpal has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/8/2023 | CCCC | $32K | -43.1% | -41.8% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
Transaction History
| ATRA | ▼ Sell | Open Market | 6,871 | $25K | 3/2/2023 | View on chart |
| CCCC | ▲ Buy | Open Market | 5,667 | $32K | 2/8/2023 | View on chart |
| ATRA | ▼ Sell | Open Market | 2,485 | $14K | 2/7/2023 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,172 | $23K | 11/16/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,083 | $5K | 11/16/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,940 | $30K | 8/16/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 5,853 | $33K | 6/8/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 4,616 | $25K | 5/17/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 966 | $5K | 5/17/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 2,272 | $22K | 3/1/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 1,491 | $15K | 3/1/2022 | View on chart |
| ATRA | ▲ Buy | Grant | 61,235 | $0 | 3/1/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 2,496 | $36K | 2/7/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 3,655 | $63K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA
Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.